MLL-rearranged acute lymphoblastic leukemia (ALL) in infants (o1 year) is the most aggressive type of childhood leukemia. To develop more suitable treatment strategies, a firm understanding of the biology underlying this disease is of utmost importance. MLL-rearranged ALL displays a unique gene expression profile, partly explained by erroneous histone modifications. We recently showed that t(4;11)-positive infant ALL is also characterized by pronounced promoter CpG hypermethylation. In this study, we investigated whether this widespread hypermethylation also affected microRNA (miRNA) expression. We identified 11 miRNAs that were downregulated in t(4;11)-positive infant ALL as a consequence of CpG hypermethylation. Seven of these miRNAs were re-activated after exposure to the de-methylating agent Zebularine. Interestingly, five of these miRNAs are associated either with MLL or MLL fusions, and for miR-152 we found both MLL and DNA methyltransferase 1 (DNMT1) as potential targeted genes. Finally, a high degree of methylation of the miR-152 CpG island was strongly correlated with a poor clinical outcome. Our data suggests that inhibitors of methylation have a potential beyond re-expression of hypermethylated protein-coding genes in t(4;11)-positive infant ALL. In this study, we provide additional evidence that they should be tested for their efficacy in MLL-rearranged infant ALL in in vivo models.
Introduction
Hematological malignancies, characterized by chromosomal translocations involving the Mixed Lineage Leukemia (MLL) gene are rare among children and typically affect infants (o1 year of age). 1 Approximately 80% of infants diagnosed with acute lymphoblastic leukemia (ALL) carry such MLL rearrangements that independently contribute to disease aggressiveness. 2 The most frequent MLL translocation in infant ALL is t(4;11), fusing the N-terminus of the MLL gene to the C-terminus of transcription factor AF4, generating the oncogenic fusion protein MLL-AF4. Normally wild-type MLL functions as an important epigenetic regulator; a histone methyltransferase facilitating histone 3 tri-methylation at lysine 4 (H3K4me3). 3 As a result of MLL translocations, wild-type MLL becomes disrupted and its normal function is compromised by the loss of its methyltransferase domain. Instead, the MLL fusion proteins MLL-AF4, MLL-ENL, MLL-AF9 and MLL-AF10 recruit alternative histone methyltransferases like DOT1L, leading to histone 3 di-methylation at lysine 79 (H3K79me2). 4, 5 In turn these illegitimate histone modifications lead to inappropriate activation of numerous genes, establishing a unique gene expression profile presumably favoring leukemia development. 6, 7 Apart from gene activation guided by erroneous histone modifications, we recently showed that in MLL-rearranged infant ALL also numerous genes are inactivated or silenced as a consequence of DNA hypermethylation. 8 This is especially true for t(4;11)-positive infant ALL, in which the degree of genome-wide promoter hypermethylation seemed to be associated with an increased risk of relapse. 8 In this study, we asked whether the wide-spread hypermethylation patterns as observed in MLL-rearranged infant ALL could also have affected microRNA (miRNA) expression. Hypothetically, hypermethylation or silencing of miRNAs may successively lead to abnormally activated miRNA-targeted genes, and hence, may further have contributed to the unique gene expression profile of MLL-rearranged infant ALL. To test this, we here studied the relation between two forces representing hallmark discoveries of contemporary biology: DNA methylation and miRNA expression. 9 MiRNAs are small (B22-nucleotides) RNA molecules that regulate the translation of over 60% of all human protein-coding genes 10 via transcript destabilization and/or translational repression. Increasing evidence has emerged that deregulated miRNA expression contributes to the development of various hematological malignancies. [11] [12] [13] Aberrant expression of certain miRNAs has also been observed in leukemias characterized by MLL translocations. For instance miR-196b was found to be over-expressed in MLL-rearranged infant ALL compared with other types of childhood precursor B-ALL, 12 and seemed to participate in leukemogenesis by stimulating proliferation while blocking differentiation in hematopoietic progenitor cells. 14 More recently, upregulation of the entire miR-17-92 cluster was described in MLL-rearranged leukemias. 15 Strong binding of the MLL fusion protein to this miRNA cluster led to inhibition of apoptosis, and promoted proliferation by regulation of the relevant target genes.
So far most studies in MLL-rearranged leukemia focused on miRNA overexpression. 12, 15, 16 However, in a recent genomewide miRNA study we found putative tumor suppressing miRNAs, such as let-7b and miR-708, to be downregulated in MLL-rearranged ALL, and to be associated with oncogene upregulation. 12 Therefore, this study was designed to explore the silencing effects of genome-wide CpG island hypermethylation on miRNA expression, and the ability of the de-methylating agent Zebularine to restore miRNA activity.
Patients and methods

Patient samples
We studied 22 newly diagnosed infants (o1 year) with t(4;11)-positive ALL enrolled in the international INTERFANT-99 treatment protocol. 1 To make a valid comparison, wild-type MLL infant ALL samples (n ¼ 10) and non-MLL childhood precursor B-cell ALL samples (n ¼ 10) from our cell bank were added. Mononuclear cells were isolated from bone marrow samples using sucrose density centrifugation. 17 The percentage of leukemic cells was determined by May-Grü nwald-Giemsa (Merck, Darmstadt, Germany) stained cytospins, and in case blast percentages were below 90%, samples were enriched by elimination of non-malignant cells using immunomagnetic beads (Dynabeads, Dynal, ASA, Oslo, Norway). In the case of contaminating monocytes the CD14 marker was used, CD15 in the case of myeloid cells and E-1 antigen in the case of erythroid cells. 18 DNA methylation microarrays and gene expression microarrays were performed for 22 infant ALL patients. In addition, CpG microarrays were performed for 10 wild-type MLL infant ALL samples and 10 non-MLL childhood precursor B-cell ALL samples. Because of restricted availability of patient material, miRNA expression assays were performed for only five infant ALL patients. The miRNA expression assay specific for miR-152 could be performed for 13 infant ALL patients. Normal bone marrow samples obtained from seven non-leukemic pediatric patients were included as controls. All samples were collected after approval of the institutional review board and informed consent from parents or legal guardians.
Cell line culture and Zebularine treatment
SEMK2 is subclone of the SEM cell line, which is a t(4;11)-positive precursor B-ALL cell line derived from a 5-year-old girl at relapse 19, 20 (kindly provided by Dr Scott Armstrong (Dana Farber Cancer Institute, Boston, MA, USA)). The cell line was maintained as a suspension culture in RPMI 1640 with L-alanyl-L-glutamine (Invitrogen, Breda, the Netherlands) supplemented with 10% FCS (Integro, Zaandam, the Netherlands), 100 IU/ml penicillin, 100 mg/ml streptomycin and 0.125 mg/ml fungizone (Invitrogen) at 37 1C in humidified air containing 5% CO 2 . Cells were exposed to 100 mM of the de-methylating agent Zebularine 21 for 3, 6 or 10 days, whereas control samples were unexposed. Cell viability was assessed using the trypan blue exclusion method.
Isolation and purification of DNA and RNA Genomic DNA and total cellular RNA were extracted using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. The quality of the extracted DNA was assessed on 1.0% agarose gels, and the RNA integrity on a Agilent 2100 Bio-analyzer using RNA 6000 Nano Assay LabChips (Agilent, Amstelveen, The Netherlands). All RNA samples had an RNA Integrity Number of X7.5.
Differential methylation hybridization for assessment of CpG island methylation
Extracted genomic DNA was used to assess the methylation status of CpG islands associated with miR-genes by the methylation-sensitive restriction enzyme-based differential methylation hybridization procedure, using 244 K CpG island microarrays (Agilent Technologies, Santa Clara, CA, USA). 8 These high-resolution CpG microarrays contain 243 497 60-mer oligonucleotide probes, including 1118 probes corresponding to 122 miR-genes encoding 113 mature miRNAs. Some of the probes represent CpG islands (embedded in between different miR-genes) associated with two or three mature miRNAs belonging to the same miRNA cluster. A genomic DNA pool derived from healthy males (n ¼ 5) and females (n ¼ 5) (Promega Benelux BV, Leiden, The Netherlands) was used as a common reference. Labeling and hybridization procedures were performed as reported previously. 8 Data extraction was performed using Agilent Feature Extraction 9.5.3 software and unprocessed genome-wide DNA methylation data was deposited in the NCBI Gene Expression Omnibus under the GEO Series accession number GSE18400, as part of our recent study on DNA methylation patterns in MLL-rearranged infant ALL. 8 CpG island methylation data are presented as normalized log ratios of patient signal divided by the common reference signal.
miRNA expression analyses
Expression levels of 365 miRNAs were determined by using the Taqman MicroRNA array-platform based on stem-loop quantitative real-time PCR (RT-PCR) (Applied Biosystems, Foster City, CA, USA). 22 Reactions were performed according to the manufacturer's guidelines and the amplification of obtained cDNA was monitored on an ABI 7900HT Sequence Detection System (Applied Biosystems). MiRNA expression levels were determined in t(4;11)-positive infant ALL (n ¼ 5), and normal bone marrow (n ¼ 7) samples, as well as in Zebularine-treated and -untreated SEMK2 cells. An additional set of 13 t(4;11)-positive patients was examined for miR-152 expression by using a separate assay based on stem-loop quantitative RT-PCR specifically for miR-152. This assay was performed in duplicate for all patients. The mean of Ct-values for snoR-13 and -14 (Taqman MicroRNA array), and snoR-1 (miR-152 assay) were used as a reference for input RNA. The expression was calculated as a percentage of snoRNA: 2 ÀDCt Â 100, in which DCt is equal to 'Ct miRNA minus Ct control snoRNA '. Hypermethylated miRNAs were considered re-expressed by de-methylation when 42-fold increases in expression were observed for at least two time points (3, 6 or 10 days) of Zebularine treatment.
Gene expression analyses using Affymetrix GeneChips
Affymetrix HGU133 plus 2.0 GeneChips (Santa Clara, CA, USA) were used to study mRNA expression levels of the potential miRNA-target genes DNA methyltransferase 1 (DNMT1), MLL, ZEB2 and HOXA3 in t(4;11)-positive infant ALL patients (n ¼ 22), and in normal bone marrow samples (n ¼ 7). Data were processed as described before 7 and raw infant ALL gene expression data was deposited in the NCBI Gene Expression Omnibus under the GEO Series accession number GSE 19475, as part of one of our recent studies. 7 
Quantitative real-time PCR analysis
Total RNA was reverse transcribed as described before 17 and the obtained cDNA was used to quantify MLL, DNMT1, ZEB2 and HOXA3 mRNA expression in cell line SEMK2, using quantitative RT-PCR analysis. B2M, encoding human beta-2-Microglobulin, was used as a housekeeping reference gene. All oligonucleotides were designed using the OLIGO 6.22 software (Molecular Biology Insights, Cascade, CA, USA) and primer combinations are listed in Supplemental Table 1S . PCR products were amplified and stained using the DyNAmo SYBR Green qPCR kit (Finnzymes, Espoo, Finland) according to the manufacturer's recommendations, and detected on an ABI 7900HT Sequence Detection System (Applied Biosystems). 7 Per experiment, samples were analyzed in duplicate and all experiments were conducted twice. Highly expressed miRNA-targeted genes were considered downregulated by re-activation of the miRNA when mRNA expression was at least two-fold decreased after Zebularine treatment.
Statistical analyses
Normalization of the CpG island microarray data was performed using global locally weighted scatterplot smoothing (loess) normalization. 23 Differentially methylated CpG island loci and differentially expressed miRNAs were identified using linear models for microarray data (limma) as previously described. 8, 24 Differential methylation and expression was regarded significant at P-values (adjusted for multiple testing according to the step-up procedure of Benjamini and Hochberg 25 ) of o0.05 (that is, False Discovery Rate (FDR) o0.05). All statistical analyses were performed in the statistical environment R using Bioconductor packages (R Development Core Team, 2007). Heatmaps were generated in GenePattern version 3.1.2 and principal component plots were produced using Genemath XT 1.6.1. software (Applied Maths, Inc., Austin, TX, USA).
The risk of relapse and the overall survival were computed with the Kaplan-Meier estimator. Overall survival was defined as the time from diagnosis until death or the last follow-up. The log-rank test was used to compare outcomes between different patient groups. SPSS 16.0 statistical software (SPSS Inc., Chicago, IL, USA) was used for computation of survival statistics.
Results
CpG island hypermethylation at miRNA loci in t(4;11)-positive infant ALL
We previously showed that MLL-rearranged infant ALL patients carrying translocation t(4;11) exhibit severely hypermethylated genomes. 8 In this study, we investigated whether the genomewide deregulation of DNA methylation also affected miRNA activity. For this, multiple data sets were successively analyzed following the flowchart shown in Figure 1 . First, an unsupervised principle component analysis using all the 1118 oligonucleotide probes related to 122 miR-genes (encoding 113 mature miRNAs) present on the 244K CpG island microarray (Agilent), readily separated the data into two groups corresponding to t(4;11)-positive infant ALL (n ¼ 22) and normal bone marrow samples (n ¼ 7) (Supplemental Figure 1S ). Fifty-nine out of these 122 miR-genes encoding 55 mature miRNAs were significantly hypermethylated (FDR o0.05) in t(4;11)-positive infant ALL cases compared with normal bone marrows ( Figure 2a ). Agilent probe IDs, log-fold changes in methylation and P-values are listed in Supplemental Table 2S . As shown in Figure 2a , among the t(4;11)-positive infant ALL samples two subgroups could be identified that either displayed heavy (n ¼ 7) or light (n ¼ 15) miR-gene methylation. Although we observed a similar phenomenon in our study of the methylation patterns of protein-coding gene promoters, 8 the separation shown in this study between heavy and light miR-gene methylation is more pronounced (Figures 2a and b) . Table 2S ), presumably as a consequence of CpG island hypermethylation. 26 For some miRNAs, such as miR-148a, miR-503 and miR-432, 4100-fold downregulated expression was observed in t(4;11)-positive infant ALL as compared with normal bone marrow.
Downregulated expression of hypermethylated miR-genes
Responsiveness of miRNA loci to de-methylation by Zebularine
In t(4;11)-positive infant ALL, the expression of the majority of genes transcriptionally silenced by promoter hypermethylation could be re-activated by the DNA methyltransferase inhibitor Zebularine. 8 In this study, we examined the responsiveness of the silenced and hypermethylated miRNAs (Figure 2c ) to de-methylation. For this, the t(4;11)-positive precursor B-ALL cell line SEMK2 (a subclone of the SEM cell line) was exposed to 100 mM of Zebularine for 3, 6 or 10 days. At these consecutive time points both CpG island methylation and miRNA expression were determined. Nine miRNA loci could be de-methylated by Zebularine (Supplementary Figure 2SA) , and for seven of these, that is, miR-200b, miR200a, miR429, miR-152, miR-10a, miR-503 and miR-432, expression was increased. (Table 1 , Supplementary Figure 2SB) . Interestingly, hypermethylation at these miR-gene loci turned out to be specific for t(4;11)-positive infant ALL when compared with wild-type MLL infant ALL samples (n ¼ 10) and non-MLL childhood ALL samples (n ¼ 10) (Figure 3) . Zebularine treatment 9/11 miR-genes de-methylated 7/9 mature miRNAs re-expressed (Table 1) 46/55 miRNAs covered by stem-loop quantitative RT-PCR Figure 1 Flowchart showing the sequential analyses performed in this study. Several sequential analyses were performed on different data sets, and miRNAs were selected for further evaluation on the basis of the following criteria: hypermethylated miRNAs are transcriptionally silenced, and exposure to the DNA methyltransferase inhibitor Zebularine results in de-methylation and re-expression. Seven miRNAs met these criteria.
De-methylation and re-expression of miRNA clusters About 40% of all miRNAs are found to be organized in clusters on human chromosomes. 27 By definition, miRNAs encoded less than 3 kb apart from one another are considered to be clustered and often are collectively expressed at comparable levels. 9, 27 Five of the seven miRNAs that were re-expressed upon de-methylation, seemed to be part of such miRNA clusters. Figure 4c ). Interestingly, neighboring miRNAs belonging to the same cluster also seem to be affected in a similar manner, albeit in some cases (for example, miR-127 and miR-433) less significantly.
The two remaining miRNAs, miR-10a and miR-152, are both located on chromosome 17q21.32, however, the genomic distance between these miRNAs exceeds with 4500 kb the limit of 3 kb and they should therefore be considered as individual entities. Figure 3C ). Samples were ordered using hierarchical cluster analysis (Euclidean distance, complete linkage). (b) Principal component analyses (PCA) using the 59 hypermethylated miR-genes separating heavily (red, n ¼ 7) and lightly (pink, n ¼ 15) methylated t(4;11)-positive infant ALL, and normal bone marrow samples (blue, n ¼ 7). On the basis of the first three components of the PCA explaining 62.5% of the total variance, the samples were visualized. (c) Heatmap displaying the expression of miRNAs that were significantly downregulated in t(4;11)-positive infant ALL samples (n ¼ 5) as compared with normal bone marrows (n ¼ 7) (FDRo0.05). Relative expression levels are shown in red (high) and blue (low). MiRNA expression profiling could only be performed for five patients because of restricted availability of patient material. Among the five patients, three were lightly methylated patients and two were heavily methylated patients. Similarly as observed in our previous study, the separation between heavily and lightly methylated patients is not reflected at the expression level. 8 outcome in precursor B-ALL. 28 In this study, we present a similar finding in MLL-rearranged infant ALL involving miR-152. Although this miRNA locus is consistently methylated in all t(4;11)-positive infant ALL samples tested (Figure 1a) , the magnitude of methylation and expression varied per patient (Figures 5a and b) . Using the median log ratio of miR-152 methylation as obtained from CpG microarray data (Figure 5a) as the cut-off value, t(4;11)-positive patients were divided into two groups displaying either high or low degrees of methylation. The median miRNA expression was twofold lower in the group with a high degree of methylation (FDRo0.05) (Figure 5c ). Furthermore, heavy methylation of the miR-152 CpG island was associated with an increased risk of relapse (P ¼ 0.0016) (Figure 5d ) and a reduced overall survival (Po0.001) (Figure 5e ). The two known prognostic factors in infant ALL, such as age o6 months and white blood cell (WBC) count 4300 Â 10 9 /l (Pieters et al 1 ) did not differ significantly between the groups (Supplementary Table 3S ). Although convincing, these results have to be interpreted with caution, given the low number of patients.
Potential target genes of miR-152
Encouraged by the clinical relevance of the methylation status of the miR-152 CpG island, we set out to identify possible miRNAtargeted genes by using the algorithms TargetScan and Pictar, 29 which base their prediction on sequence homology between miRNA and potential mRNA target. Both algorithms showed that DNMT1, also known as CXXC9, on chromosome 19p13.2 represents a possible target for miR-152 (probability of conserved targeting (P CT , a measure for assessing the biological relevance of predicted miRNA-target interactions): 10 0.77). Moreover, DNMT1 has recently been verified as a target of miR-152 in hepatobiliary cancer. 30 On the basis of known sequence similarity, we investigated whether the MLL gene on chromosome 11q23, alias CXXC7, could be another miR-152 targeted gene. Interestingly, the seed sequence of miR-152 seemed entirely present in the 3 0 untranslated regions of both DNMT1 and MLL (P CT : 0.86) (Figure 6a) .
Interestingly, miR-148, the other member of the highly conserved miR-148/152 family, which is also downregulated due to CpG hypermethylation in t(4;11)-positive infant ALL (Figures 6b and c) , has the same seed sequence as miR-152 and may therefore also target DNMT1 and MLL (Figure 6a ), which has already been proven for DNMT1.
30 DNMT1 and MLL are highly expressed in t(4;11)-positive infant ALL patients ( Figures  6d and e) , and de-methylation of miR-152 by Zebularine leading to upregulation of miR-152 readily resulted in downregulation of mRNA expression of these genes (Figures 6f and g ). In contrast to its family member miR-152, miR-148 could not be re-activated after exposure to Zebularine for 10 days.
ZEB2 and HOXA3 as potential miRNA-target genes in t(4;11)-positive infant ALL According to literature the zinc finger E-box binding homeobox 2 (ZEB2) gene is the best-known validated target gene of the miR-200b/a-429 cluster, 31 and the homeobox A3 (HOXA3) gene has been described as a potential miR-10a targeted gene.
32 Table 1 Zebularine induced de-methylation and re-expression of silenced miRNAs. Abbreviations: FDR, false discovery rate; miRNA, microRNA; nBM, normal bone marrow. Table shows hypermethylated miRNAs that were transcriptionally silenced, but de-methylated and re-expressed upon Zebularine treatment. Expression levels were measured by quantitative RT-PCR, and fold-changes between t(4;11)-positive ALL and nBM, as well as expression levels in the SEMK2 cell line before (Z0) and after treatment (for 3 (Z3), 6 (Z6) or 10 (Z10) days) are shown. MiRNAs were considered re-expressed by Zebularine when the expression was increased more than twofold for at least two time points during treatment. Both of these genes are known to be highly expressed in t(4;11)-positive infant ALL 5,7 which was validated on our t(4;11)-positive infant ALL cohort (Affymetrix GeneChips) (Supplemental Figures 3SA and B) . After Zebularine treatment the miR 200b/a-429 cluster was upregulated, as well as miR-10a (Table 1) , and ZEB2 expression was clearly downregulated (Supplemental Figure 3SC ) whereas HOXA3 expression was only marginally decreased (Supplemental Figure 3SD) . Table 2S ).
Discussion
MLL-rearranged ALL in infants represents a high-risk type of childhood leukemia characterized by a complex biology. Initiating transformation, the MLL fusion protein alters normal MLL histone methyltransferase activity guided by the fusion partner. In turn, these inappropriate histone modifications induce aberrant transcription of multiple genes, resulting in highly characteristic gene expression profiles. 6, 7 Opposing widespread gene activation, we recently demonstrated that vast numbers of genes are epigenetically silenced by promoter hypermethylation, 8 which was recently confirmed in an independent study by others. 33 Genome-wide hypermethylation is especially apparent in t(4;11)-positive infant ALL, and as shown in this study extends its effects on miRNA expression.
Comparing t(4;11)-positive infant ALL with healthy bone marrow samples, a total of 59 out of 122 analyzed miR-genes seemed to be significantly hypermethylated. Seven of these miRNAs were selected for further evaluation because they were transcriptionally silenced, and exposure to the DNA methyltransferase inhibitor Zebularine resulted in their de-methylation and re-expression: miR-200b, miR200a, miR429, miR-152, miR-10a, miR-503 and miR-432 (Table 1) .
Interestingly, some of these miRNAs have been described to function as tumor suppressing miRNAs. For instance, miR-432 is located within the large miR-127 cluster (Figure 4c ) that was previously shown to be silenced in various malignancies by CpG island hypermethylation and aberrant histone modifications. 9 In that study, re-expression of miR-127 resulted in downregulation of the proto-oncogene B-cell CLL/lymphoma 6 (BCL6) at the protein level. 9 In addition, downregulation of miR200b in human cancers leads to disease progression via elevated expression of the two E-cadherin transcriptional repressors: ZEB1 and ZEB2. 31 Importantly, ZEB2 is highly expressed in t(4;11)-positive ALL as a consequence of MLL-AF4-driven histone modifications. 5 Our data demonstrate both ZEB2 downregulation (Supplementary Figure 3SC) and re-activation of miR-200b (Supplementary Figure 2SB) by Zebularine, suggesting that MLL translocation-induced transcription involves the concerted regulation of both chromatin structure and miRNA activity.
Another example of MLL fusion-driven miRNA regulation involves the polycistronic miR-424-503 cluster. In t(9;11)-positive myeloid leukemias, miR-424 expression was repressed by the MLL-AF9 fusion protein. 34 In this study, we show that the miR-424-503 cluster is downregulated by CpG island hypermethylation in t(4;11)-positive ALL, possibly directed by the MLL-AF4 fusion. Likewise, miR-10a is downregulated in MLL-rearranged acute myeloid leukemia. 35 In line with these observations, we found miR-10a to be downregulated in t(4;11)-positive infant ALL. Although miR-10a is located within the HOXB cluster, one of its putative targets is HOXA3.
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In concordance with miR-10a silencing, HOXA3 expression is elevated in t(4;11)-positive infant ALL patients (Supplemental Figure 3SB) . However, re-activation of miR-10a by de-methylation only marginally repressed HOXA3 expression at the mRNA level, suggesting that miR-10a exerts its inhibition on putative target HOXA3 largely on the protein level. Alternatively, additional forces retain the expression of this gene.
Of high interest it was that we identified the wild-type MLL gene as a potential target of miR-152. A recent report suggests . P values are from limma models. (f) DNMT1, and (g) MLL mRNA expression levels relative to the housekeeping reference gene B2M were determined by RT-PCR in the t(4;11)-positive cell line SEMK2 before and after exposure for 3, 6 and 10 consecutive days to 100 mM of Zebularine. Expression levels in unexposed SEMK2 cells were set to 100%. Highly expressed miRNA targeted genes were considered downregulated by re-activation of the miRNA when mRNA expression was at least twofold decreased after Zebularine treatment.
that co-expression of wild-type MLL is required for MLL-AF9-induced leukemogenesis. 36 Whether wild-type MLL is also required for the development or maintenance of t(4;11)-positive leukemias remains uncertain. However, as we show in this study, epigenetic inactivation of miR-152 at least prevents the downregulation of wild-type MLL. Treatment with the de-methylating agent Zebularine induced expression of miR-152 and downregulation of wild-type MLL at the mRNA level. Moreover, the other miR-148/152 family member miR-148 uses the same 'seed' sequence as miR-152, and therefore may also target the MLL gene (Figure 6a ). MiR-148 is also downregulated as a consequence of CpG island hypermethylation in t(4;11)-positive infant ALL (Figures 6b and c) , which may have further obstructed downregulation of wild-type MLL. In addition, in case of an MLL translocation, the N-terminal region of the MLL gene is usually retained in the fusion protein, whereas the C-terminus containing the 3 0 untranslated regions is lost. Therefore, miR-148/152 would not be able to target the leukemic MLL-AF4 fusion. However, in the majority of t(4;11)-positive ALL samples, also the reciprocal AF4-MLL transcript is present, 37 and from recently published mouse models it seem that the AF4-MLL fusion is essential for leukemic transformation. 38 Hypothetically, besides targeting wild-type MLL, miR-152 may target the oncogenic reciprocal AF4-MLL fusion product. The fact that the AF4-MLL transcript is detected in 80% of t(4;11)-positive ALL samples indicates that this reciprocal transcript may contribute to the leukemogenic transformation into a full-blown leukemia, but may not be essential for further maintenance of the leukemia. Epigenetic silencing of miR-152 and possibly miR-148 may therefore have contributed to this process by facilitating AF4-MLL-driven induction of leukemic transformation. The selected miRNAs were not methylated in wild-type MLL infant ALL patients and non-MLL childhood ALL patients (Figure 3 ). In concordance with this none of the selected miRNAs in this study was found to be associated with CpG island hypermethylation in adult and pediatric precursor B-cell ALL patients in a previous study, 28 which provides additional evidence that the miRNAs identified in this study are specific for t(4;11)-positive ALL. MiR-152 has been described before to be silenced due to CpG hypermethylation in cancer before. 39 Apart from the associations of the selected miRNAs with MLL and MLL fusions, another notable feature stands out. The expression of at least three out of these miRNAs seems to be regulated by the genes executing DNA methylation: miR-200b, miR-200a and miR-10a were most significantly upregulated in a Dnmt1 À /Dnmt3 À knockout mouse model. 32 As DNMT1 and DNMT3 (DNA methyltransferase 1 and 3) facilitate maintenance and de novo DNA methylation, respectively, expression of these miRNAs is evidently controlled by the epigenetic force of DNA methylation. MiR-152 seems to be an effector of the epigenetic machinery itself as one of its putative targets is DNMT1.
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Therefore miR-152 can be added to the growing list of so-called 'epi-miRNAs', such as miR-29b and miR-290, which control the regulation of DNMTs. 40 MiR-148 has recently been added to this list of epigenetic effector miRNAs because it targets DNMT3b. 41 As we have shown in this study, the degree of miR-152 methylation varies among t(4;11)-positive infant ALL samples and is highly predictive for clinical outcome. Similarly, we recently found that the degree of genome-wide promoter methylation also varies among MLL-rearranged infant ALL and that patients with heavily methylated genomes are at extremely high risk of disease relapse. 8 Heavily methylated cases displayed a higher degree of methylation of the miR-152 CpG island (Supplemental Figure 4S) . Thus, the varying levels of miR-152 methylation and DNMT1 expression may determine the severity of genome-wide methylation. Zebularine is a cytidine analog that requires incorporation into the DNA where it covalently binds DNMT1, and protein levels of this protein will be reduced directly by this mechanism. Thereafter, indirectly, through re-expression of miR-152, the conventional RNA silencing mechanism will downregulate the expression of DNMT1 even further. Zebularine-induced re-activation of miR-152 that targets DNMT1 may thus enhance the efficiency of the compound and explain its recently demonstrated potential in MLL-rearranged infant ALL. 8 Until recently, it was believed that the de-methylating functions of DNMT inhibitors, such as 5-Azacytidine, Decitabine (5-Aza-deoxycytidine) and Zebularine are limited to hypermethylated (tumor suppressor) genes. In this study we show that Zebularine, through re-activation of important hypermethylated miRNAs, is able to downregulate proto-oncogenes in MLL-rearranged infant ALL. Obviously, the stability of Zebularine was a key factor in allowing the re-expression of silenced miRNAs genes, which peaks after 10 days. This stresses the imperative need to test Zebularine or comparable compounds in mouse models and subsequent clinical trials in infant leukemia.
Besides the previously published hypermethylation at proteincoding genes, 8 in this study we showed that the aberrant DNA methylation in t(4;11)-positive infant ALL extended into methylation at miRNA loci. We identified miRNAs that were inactivated because of CpG island hypermethylation and the majority of these miRNAs have been found to be associated with the MLL gene or MLL-rearranged leukemia, implying an important role for the MLL-AF4 fusion in the deregulation of these miRNAs. We further show that the silenced status of miR-152 has impact on the survival of t(4;11)-positive infant ALL patients. This silenced status can be reversed by Zebularine. Altogether, our study indicates that although miRNAs are small in size, they have major implications in t(4;11)-positive infant ALL. This emphasizes the need for further investigation of de-methylating agents, like Zebularine, to improve the treatment of these young patients with leukemia.
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